Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Deucravacitinib Tablet Formulations
NCT04249284Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2020
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of deucravacitinib in plaque psoriasis (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum concentration for BMS-986165 in plasma up to 18 days, Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration up to 18 days and 1 more. Started Feb 2020; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04249284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04249284.